WuXi AppTec Announces Further Grant of H Share Awards

TipRanks06:09 ET

WUXI APPTEC (02359.HK): 0.104 million reward shares have been granted to 17 selected participants.

Gelonghui, January 10th丨WUXI APPTEC (02359.HK) announced that as of the date of this announcement, 104,253 awarded shares have been granted to 17 selected participants, accounting for approximately 0.027% of the total issued H shares of the company and approximately 0.0036% of the total issued share capital (further grants).

Gelonghui Finance05:52 ET

Express News | BlackRock, Inc's Long Position in H Shares of WuXi AppTec Co Reduced to 4.70% on Jan 7 From 5.26% - HKEX

Reuters04:45 ET

Hong Kong stocks moved differently | Most CRO Concept stocks rose, the momentum for the development of biopharmaceuticals continues, UBS Group is Bullish on the recent earnings prospects of the CRO Industry.

Most CRO concept stocks have risen. As of the time of writing, WUXI BIO (02269) is up 3.28% at HKD 17.02; WUXI APPTEC (02359) is up 3.03% at HKD 52.65; PHARMARON (03759) is up 1.72% at HKD 13.02; Asymchem Laboratories (06821) is up 1.16% at HKD 47.85.

Zhitong FinanceJan 8 22:24 ET

CMB International: With continued policy efforts, Bullish on the rebound of China Meheco Group's valuation.

Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a high-elasticity Industry, is expected to outperform the market in 2025.

Zhitong FinanceJan 8 03:34 ET

[Brokerage Focus] CMB International stated that the pharmaceutical industry is expected to outperform the market in 2025, benefiting from overseas interest rate cuts and improvements in the domestic macro environment.

Jinwu Finance News | Zh Xia International released a Research Report stating that on January 3, the General Office of the State Council issued the "Opinions on Deepening the Reform of Pharmaceutical and Medical Instruments Regulation to Promote High-Quality Development of the Pharmaceutical Industry." The policy mentions deepening the reform of the entire process of pharmaceutical and medical instruments regulation, accelerating the establishment of a unified national market in the field of pharmaceutical and medical instruments, creating an innovative ecosystem with Global competitiveness, and promoting the transition of China from a major pharmaceutical country to a strong pharmaceutical country. The policy aims for significant improvements in the quality and efficiency of the review and approval of Innovative Drugs and medical instruments by 2027, establishing a regulatory system that aligns with pharmaceutical innovation and industrial development. By 2035, the pharmaceutical industry will have...

King Wu Financial NewsJan 8 02:37 ET